| Cas No.: | 540737-29-9 |
| 名称: | 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |
| 别名: | CP-690550; Tofacitinib; tasocitinib |
| SMILES: | C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O |
| 分子式: | C22H28N6O8 |
| 分子量: | 504.49 |
| 纯度: | |
| 保存条件: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | |
| In Vivo: | |
| In Vitro: | |
| References: | Tofacitinib (trade name Xeljanz, Formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved For the treatment of rheumatoid arthritis (RA) in the United States and is being studied For treatment of psoriasis |
| Kinase Assay: | |
| Cell Assay: | |
| Animal Administration: | |
| References: |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
